- Home
- RPRX vs ONON Comparison
RPRX vs ONON Comparison
Compare RPRX & ONON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- ONON
- Stock Information
- Founded
- RPRX 1996
- ONON 2010
- Country
- RPRX United States
- ONON Switzerland
- Employees
- RPRX N/A
- ONON N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- ONON Shoe Manufacturing
- Sector
- RPRX Health Care
- ONON Consumer Discretionary
- Exchange
- RPRX Nasdaq
- ONON Nasdaq
- Market Cap
- RPRX 16.2B
- ONON 11.4B
- IPO Year
- RPRX 2020
- ONON 2021
- Fundamental
- Price
- RPRX $39.05
- ONON $41.44
- Analyst Decision
- RPRX Strong Buy
- ONON Strong Buy
- Analyst Count
- RPRX 3
- ONON 20
- Target Price
- RPRX $46.00
- ONON $62.50
- AVG Volume (30 Days)
- RPRX 3.8M
- ONON 10.2M
- Earning Date
- RPRX 11-05-2025
- ONON 11-12-2025
- Dividend Yield
- RPRX 2.25%
- ONON N/A
- EPS Growth
- RPRX N/A
- ONON 74.51
- EPS
- RPRX 1.75
- ONON 0.84
- Revenue
- RPRX $2,349,844,000.00
- ONON $3,607,815,596.00
- Revenue This Year
- RPRX $36.16
- ONON $30.53
- Revenue Next Year
- RPRX $2.04
- ONON $23.83
- P/E Ratio
- RPRX $22.36
- ONON $49.03
- Revenue Growth
- RPRX 3.70
- ONON 33.26
- 52 Week Low
- RPRX $24.05
- ONON $34.38
- 52 Week High
- RPRX $41.24
- ONON $64.05
- Technical
- Relative Strength Index (RSI)
- RPRX 57.65
- ONON 56.19
- Support Level
- RPRX $38.82
- ONON $34.38
- Resistance Level
- RPRX $40.01
- ONON $44.87
- Average True Range (ATR)
- RPRX 1.21
- ONON 1.85
- MACD
- RPRX 0.06
- ONON 0.76
- Stochastic Oscillator
- RPRX 58.47
- ONON 68.35
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About ONON On Holding AG
On Holding AG is a premium performance sports brand rooted in technology, design, and impact. Its shoes, apparel, and accessories products are designed predominantly for athletic use, casual, or leisure purposes. It does not manufacture the products or the raw materials and relies instead on third-party suppliers and contract manufacturers. Geographically, it derives a majority of its revenue from the Americas and rest from Europe, Middle East and Africa and Asia-Pacific region.